Health Canada Approves Alecensaro for Aggressive Lung Cancer

Health Canada has approved Alecensaro as a monotherapy for the treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

The approval of Alecensaro is based on two pivotal Phase I/II studies, in which the treatment shrank tumors in up to 50 percent of people with ALK-positive NSCLC whose disease had worsened on crizotinib.

Alecensaro is a twice-daily oral medicine that blocks the activity of the ALK protein, which may slow down the growth and spread of NSCLC.